VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo

Biochimica et Biophysica Acta - Biomembranes

Volumn 1778, Issue 4, 2008, Pages 854-863

  Gosk, Sara ^a   Moos, Torben ^b   Gottstein, Claudia ^c   Bendas, Gerd ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immunoliposome; Tumor; Tumor xenograft model; Vascular targeting; VCAM 1

Indexed keywords

IMMUNOLIPOSOME; TRITIUM; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW; CONTROLLED STUDY; DIFFUSION; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER; MACROPHAGE; MORPHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN TARGETING; SPLEEN; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; ENDOTHELIAL CELLS; FEMALE; HUMANS; LIPOSOMES; MICE; MICE, NUDE; NEOPLASMS; ORGAN SPECIFICITY; PARTICLE SIZE; RHODAMINES; VASCULAR CELL ADHESION MOLECULE-1;

CITRUS MACROPHYLLA; MUS;

EID: 40949093071     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2007.12.021     Document Type: Article

References (58)

1. Chaplin D., Horsman M.R., and Siemann D.W. Current development status of small-molecule vascular disrupting agents. Curr. Opin. Investig. Drugs 7 (2006) 522-528
2. Thorpe P. Vascular targeting agents as cancer therapeutics. Clin. Cancer Res. 10 (2004) 415-427
3. Folkman J. Angiogenesis. Ann. Rev. Med. 57 (2006) 1-18
4. Boehm T., Folkman J., Browder T., and O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390 (1997) 404-407
5. Burrows F.J., and Thorpe P.E. Vascular targeting - a new approach to the therapy of solid tumors. Pharmacol. Ther. 64 (1994) 155-174
6. Folkman J. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 3 (1992) 65-71
7. Allen T.M. The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system. Adv. Drug Deliv. Rev. 13 (1994) 285-309
8. Kontermann R. Immunoliposomes for cancer therapy. Curr. Opin. Mol. Ther. 8 (2006) 39-45
9. Hansen C., Kao G.Y., Moase E.H., Zalipsky S., and Allen T.M. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. BBA 1239 (1995) 133-144
10. Allen T., Brandeis E., Hansen C., Kao G., and Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. BBA 1237 (1995) 99-108
11. Harding J.A., Engbers C.M., Newman M.S., Goldstein N.I., and Zalipsky S. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. BBA 1327 (1997) 181-192
12. Bendas G., Rothe U., Scherphof G.L., and Kamps J.A.A.M. The influence of repeated injections on pharmacokinetics and biodistribution of different types of sterically stabilized immunoliposomes. BBA 1609 (2003) 63-70
13. Volkel T., Holig P., Merdan T., Muller R., and Kontermann R.E. Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). BBA 1663 (2004) 158-166
14. Benzinger P., Martiny-Baron G., Reusch P., Siemeister G., Kley J.T., Marme D., Unger C., and Massing U. Targeting of endothelial KDR receptors with 3G2 immunoliposomes in vitro. BBA 1466 (2000) 71-78
15. Bloemen P.G.M., Henricks P.A.J., van Bloois L., van den Tweel M.C., Bloem A.C., Nijkamp F.P., Crommelin D.J.A., and Storm G. Adhesion molecules: a new target for immunoliposome-mediated drug delivery. FEBS Lett. 357 (1995) 140-144
16. Spragg D.D., Alford D.R., Greferath R., Larsen C.E., Lee K.-D., Gurtner G.C., Cybulsky M.I., Tosi P.F., Nicolau C., and Gimbrone Jr. M.A. Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system. PNAS 94 (1997) 8795-8800
17. Kessner S., Krause A., Rothe U., and Bendas G. Investigation of the cellular uptake of E-selectin-targeted immunoliposomes by activated human endothelial cells. BBA 1514 (2001) 177-190
18. Chiu G.N.C., Bally M.B., and Mayer L.D. Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis. BBA 1613 (2003) 115-121
19. Voinea M., Manduteanu I., Dragomir E., Capraru M., and Simionescu M. Immunoliposomes directed toward VCAM-1 interact specifically with activated endothelial cells-a potential tool for specific drug delivery. Pharm. Res. 22 (2005) 1906-1917
20. Gosk S., Gottstein C., and Bendas G. Targeting of immunoliposomes to endothelial cells expressing VCAM: a future strategy in cancer therapy. Int. J. Clin. Pharmacol. Ther. 43 (2005) 581-582
21. Everts M., Koning G.A., Kok R.J., Asgeirsdottir S.A., Vestweber D., Meijer D.K., Storm G., and Molema G. In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium. Pharm. Res. 20 (2003) 64-72
22. Scott R.C., Wang B., Nallamothu R., Pattillo C.B., Perez-Liz G., Issekutz A., Valle L.D., Wood G.C., and Kiani M.F. Targeted delivery of antibody conjugated liposomal drug carriers to rat myocardial infarction. Biotechnol. Bioeng. 96 (2007) 795-802
23. Temming K., Schiffelers R.M., Molema G., and Kok R.J. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist. Updat. 8 (2005) 381-402
24. Pastorino F., Brignole C., Di Paolo D., Nico B., Pezzolo A., Marimpietri D., Pagnan G., Piccardi F., Cilli M., Longhi R., Ribatti D., Corti A., Allen T.M., and Ponzoni M. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res. 66 (2006) 10073-10082
25. Simberg D., Duza T., Park J.H., Essler M., Pilch J., Zhang L., Derfus A.M., Yang M., Hoffman R.M., Bhatia S., Sailor M.J., and Ruoslahti E. Biomimetic amplification of nanoparticle homing to tumors. PNAS 104 (2007) 932-936
26. Kondo M., Asai T., Katanasaka Y., Sadzuka Y., Tsukada H., Ogino K., Taki T., Baba K., and Oku N. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int. J. Cancer 108 (2004) 301-306
27. Adams G.P., Schier R., McCall A.M., Simmons H.H., Horak E.M., Alpaugh R.K., Marks J.D., and Weiner L.M. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res. 61 (2001) 4750-4755
28. Zhou Y., Drummond D.C., Zou H., Hayes M.E., Adams G.P., Kirpotin D.B., and Marks J.D. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J. Mol. Biol. 371 (2007) 934-947
29. Osborn L., Hession C., Tizard R., Vassallo C., Luhowskyj S., Chi-Rosso G., and Lobb R. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 59 (1989) 1203-1211
30. Rice G.E., Munro J.M., and Bevilacqua M.P. Inducible cell adhesion molecule 110 (INCAM-110) is an endothelial receptor for lymphocytes. A CD11/CD18-independent adhesion mechanism. J. Exp. Med. 171 (1990) 1369-1374
31. Garmy-Susini B., Jin H., Zhu Y., Sung R.-J., Hwang R., and Varner J. Integrin α4β1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation. J. Clin. Invest. 115 (2005) 1542-1551
32. Jin H., Su J., Garmy-Susini B., Kleeman J., and Varner J. Integrin {alpha}4{beta}1 promotes monocyte trafficking and angiogenesis in tumors. Cancer Res. 66 (2006) 2146-2152
33. Klemke M., Weschenfelder T., Konstandin M.H., and Samstag Y. High affinity interaction of integrin alpha4beta1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers. J. Cell. Physiol. 212 (2007) 368-374
34. Kuzu I., Bicknell R., Fletcher C., and Gatter K. Expression of adhesion molecules on the endothelium of normal tissue vessels and vascular tumors. Lab. Invest. 69 (1993) 322-328
35. Ryan D., Nuccie B., Abboud C., and Winslow J. Vascular cell adhesion molecule-1 and the integrin VLA-4 mediate adhesion of human B cell precursors to cultured bone marrow adherent cells. J. Clin. Invest. 88 (1991) 995-1004
36. Seron D., Cameron J., and Haskard D. Expression of VCAM-1 in the normal and diseased kidney. Nephrol. Dial. Transplant. 6 (1991) 917-922
37. Dedrick R.L., Bodary S., and Garovoy M.R. Adhesion molecules as therapeutic targets for autoimmune diseases and transplant rejection. Exp. Opin. Biol. Ther. 3 (2003) 85-95
38. Dienst A., Grunow A., Unruh M., Rabausch B., Nor J.E., Fries J.W., and Gottstein C. Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins. J. Natl. Cancer Inst. 97 (2005) 733-747
39. Ricard I., Payet M., and Dupuis G. VCAM-1 is internalized by a clathrin-related pathway in human endothelial cells but its alpha 4 beta 1 integrin counter-receptor remains associated with the plasma membrane in human T lymphocytes. Eur. J. Immunol. 28 (1998) 1708-1718
40. Huang S.K., Lee K.D., Hong K., Friend D.S., and Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 52 (1992) 5135-5143
41. Emanuel N., Kedar E., Bolotin E., Smorodinsky N., and Barenholz Y. Targeted delivery of doxorubicin via sterically stabilized immunoliposomes: pharmacokinetics and biodistribution in tumor-bearing mice. Pharm. Res. 13 (1996) 861-868
42. Bendas G., Krause A., Bakowsky U., Vogel J., and Rothe U. Targetability of novel immunoliposomes prepared by a new antibody conjugation technique. Int. J. Pharm. 181 (1999) 79-93
43. Ames B., and Dubin D. The role of polyamines in the neutralization of bacteriophage deoxyribonucleic acid. J. Biol. Chem. 235 (1960) 769-775
44. Peterson G. A simplification of the protein assay method of Lowry et al. which is generally more applicable. Anal. Biochem. 83 (1977) 346-356
45. Denekamp J., Dasu A., and Waites A. Vasculature and microenvironmental gradients: the missing links in novel approaches to cancer therapy?. Advan. Enzyme Regul. 38 (1998) 281-299
46. Charrois G.J.R., and Allen T.M. Multiple injections of pegylated liposomal doxorubicin: pharmacokinetics and therapeutic activity. J. Pharmacol. Exp. Ther. 306 (2003) 1058-1067
47. Noguchi Y., Wu J., Duncan R., Strohalm J., Ulbrich K., Akaike T., and Maeda H. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 89 (1998) 307-314
48. Olafsen T., Kenanova V.E., and Wu A.M. Tunable pharmakokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat. Protoc. 1 (2006) 2048-2060
49. Antohe F., Heltianu C., and Simionescu M. Albumin-binding proteins of endothelial cells: immunocytochemical detection of the 18 kDA peptide. Eur. J. Cell Biol. 56 (1991) 34-42
50. Tsourkas A., Shinde-Patil V.R., Kelly K.A., Patel P., Wolley A., Allport J.R., and Weissleder R. In vivo imaging of activated endothelium using an anti-VCAM-1 magnetooptical probe. Bioconj. Chem. 16 (2005) 576-581
51. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., Marks J.D., Benz C.C., and Park J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66 (2006) 6732-6740
52. Pastorino F., Brignole C., Marimpietri D., Cilli M., Gambini C., Ribatti D., Longhi R., Allen T.M., Corti A., and Ponzoni M. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 63 (2003) 7400-7409
53. Schiffelers R.M., Koning G.A., ten Hagen T.L.M., Fens M.H.A.M., Schraa A.J., Janssen A.P.C.A., Kok R.J., Molema G., and Storm G. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Control. Release 91 (2003) 115
54. Fries J., Williams A., Atkins R., Newman W., Lipscomb M., and Collins T. Expression of VCAM-1 and E-selectin in an in vivo model of endothelial activation. Am. J. Pathol. 143 (1993) 725-737
55. Litzinger D.C., Buiting A.M.J., van Rooijen N., and Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. BBA 1190 (1994) 99-107
56. Aichele P., Zinke J., Grode L., Schwendener R.A., Kaufmann S.H.E., and Seiler P. Macrophages of the splenic marginal zone are essential for trapping of blood-borne particulate antigen but dispensable for induction of specific T cell responses. J. Immunol. 171 (2003) 1148-1155
57. Philipp J., Dienst A., Unruh M., Wagener A., Grunow A., Engert A., Fries J.W., and Gottstein C. Soluble tissue factor induces coagulation on tumor endothelial cells in vivo if coadministered with low-dose lipopolysaccharides. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 905-910
58. Hood J.D., Bednarski M., Frausto R., Guccione S., Reisfeld R.A., Xiang R., and Cheresh D.A. Tumor regression by targeted gene delivery to the neovasculature. Science 296 (2002) 2404-2407